Superior therapy response predictions for patients with low-grade glioma (LGG) using Cellworks Singula: MyCare-009-04

Singula is a superior predictor of PFS and OS in LGG patients compared to PPT. Singula can correctly identify non-responders to PPT and provide alternative therapy selections.

ASCO Meeting Library 2020